Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan 25:2024:8861126.
doi: 10.1155/2024/8861126. eCollection 2024.

Mediterranean-Oriented Dietary Intervention Is Effective to Reduce Liver Steatosis in Patients with Nonalcoholic Fatty Liver Disease: Results from an Italian Clinical Trial

Affiliations

Mediterranean-Oriented Dietary Intervention Is Effective to Reduce Liver Steatosis in Patients with Nonalcoholic Fatty Liver Disease: Results from an Italian Clinical Trial

Barbara Zanini et al. Int J Clin Pract. .

Abstract

Results: One hundred and fifty five subjects aged 20-59 years underwent (i) liver ultrasound (US), (ii) clinical and anthropometric evaluations, (iii) blood tests, and (iv) assessment of dietary habits. According to US evaluation, 73 of them had severe, moderate, or mild liver steatosis (NAFLD patients) and 82 had no liver steatosis (healthy controls). Fifty-eight NAFLD patients and 73 controls completed the study. Among NAFLD patients, 26 (45%) downgraded steatosis severity, 12 of which achieved complete steatosis regression (21%). Three of the healthy controls developed NAFLD. The NAFLD patients improved their dietary habits and reduced BMI and waist circumference, during the study period, more than healthy controls. Liver steatosis remission/regression was independent of changes in BMI or liver enzymes and was more frequent among patients with mild steatosis at baseline.

Conclusions: Mediterranean dietary advices, without a personalised meal planning, were efficient in reducing/remitting NAFLD, especially among patients with mild disease, which argues in favour of early identification and lifestyle intervention. This trial is registered with NCT03300661.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
Flowchart of the study. T0: time 0 (baseline); T3: 3 months; T6: 6 months; T9: 9 months; T12: 12 months.
Figure 2
Figure 2
Steatosis grade of NAFLD patients at baseline and after 12 months of lifestyle intervention.
Figure 3
Figure 3
Plot of Medscore distribution among NAFLD patients (continuous line) and controls (dotted line) at baseline (T0) (a) and at 12th month (T12) (b).

References

    1. European Association for the Study of the Liver Easl. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. Journal of Hepatology . 2016;64(6):1388–1402. doi: 10.1016/j.jhep.2015.11.004. - DOI - PubMed
    1. Eslam M., Newsome P. N., Sarin S. K., et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. Journal of Hepatology . 2020;73(1):202–209. doi: 10.1016/j.jhep.2020.03.039. - DOI - PubMed
    1. Estes C., Anstee Q. M., Arias-Loste M. T., et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. Journal of Hepatology . 2018;69(4):896–904. doi: 10.1016/j.jhep.2018.05.036. - DOI - PubMed
    1. Vernon G., Baranova A., Younossi Z. M. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Alimentary Pharmacology & Therapeutics . 2011;34(3):274–285. doi: 10.1111/j.1365-2036.2011.04724.x. - DOI - PubMed
    1. Maurice J., Manousou P. Non-alcoholic fatty liver disease. Clinical Medicine . 2018;18(3):245–250. doi: 10.7861/clinmedicine.18-3-245. - DOI - PMC - PubMed

Associated data